Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data.

Descripción del proyecto

Una plataforma de «apoyo a descubrimientos» extrae palabras y datos para identificar vínculos críticos

El descubrimiento científico raramente es producto de una idea luminosa fortuita, sino más bien el resultado del análisis de enormes cantidades de documentos y datos de campos interdisciplinarios. BIOXPLOR recorta el tiempo y los costes de las investigaciones y los ensayos clínicos, a la vez que aumenta considerablemente los éxitos con su plataforma de inteligencia artificial virtual experimental. Esta combina procesamiento natural del lenguaje y aprendizaje automático para acelerar la interpretación de datos a partir de documentos no estructurados (millones de artículos completos, ensayos clínicos, etc.) y datos estructurados (como bases de datos patentadas). Algunas de las múltiples tareas que lleva a cabo la plataforma son generar hipótesis y clasificar su probabilidad de éxito, investigar interrelaciones entre enfermedades, genética y fármacos, predecir indicaciones nuevas para medicamentos existentes y reacciones adversas de indicaciones nuevas.

Objetivo

BioXplor’s AI/Cognitive Software Platform accelerates and greatly reduces the cost of discovery research and clinical trials, with a primary focus on rare and inflammatory diseases data. The technology has shown a 5-25x reduction in time and 70% cost savings in pilots so far. (TLR stage 6 &7 tests in 5x Biotech and Pharma companies).
BioXplor has achieved the Seal of Excellence for our Phase I application in March 2019 (score 13.5) and November 2018 (score 13.09) submissions. Last year, we have been completed acceleration programs at UC Berkeley’s SkyDeck and at Merck, and since then significant progress in building the platform to TLR stage 7 and acquiring new customers and revenue. The platform has been successfully used in tests with 5x Pharma and biotech companies (Merck, Bayer, Novartis, Abcam, EdemedX), and we have 5 new leads, for our platform for Discovery applications (antibodies, recombinant proteins, biomarker discovery, immunoassays, drug target ID) and Clinical applications (indication expansion, super-responder ID for drug-repositioning, and patient stratification for Biosimilars, all in inflammation projects with Biotech and Pharma). The current submission is aimed towards bringing BioXplor’s Platform to TLR stage 8, and deploying the our fully tested solution in operational environments at Pharma, Biotech and Academic Research Institutes, for which we are already negotiating pre-orders including 3 year multiyear contracts and 5-10 year partnerships. We have since partnered UC Berkeley, gained access to clinical trials patient data from a major pharma, become a discovery forum member with the 100K Genomes Project, and been selected as a consortium partner for an EU project in the oncology space. We have built a pipeline of EUR750k, with 2019 revenues projected at EUR500k and project revenues of $2M by 2021. We have been requested to deliver the solution to manage 15-20 clinical trials (secondary use of data) for a Top 2 Pharma company

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

SME-1 - SME instrument phase 1

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-EIC-SMEInst-2018-2020

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

BIOXPLOR LIMITED
Aportación neta de la UEn
€ 50 000,00
Dirección
9C THE BOTTLEWORKS
Dublin 4 Dublin
Irlanda
Pyme
Sí
Región
Ireland Eastern and Midland Dublin
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 71 429,00